Ubiquitin is a possible new predictive marker for the recurrence of human hepatocellular carcinoma

Liver

Volumn 22, Issue 5, 2002, Pages 413-418

  Shirahashi, Hitoshi ^a   Sakaida, Isao ^a   Terai, Shuji ^a   Hironaka, Koji ^a   Kusano, Noriyoshi ^a   Okita, Kiwamu ^a  

^a YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; PIVKA II; Recurrence; Tumor marker; Ubiquitin

Indexed keywords

KI 67 ANTIGEN; PROTEIN INDUCED BY VITAMIN K ABSENCE II; TUMOR MARKER; UBIQUITIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CHRONIC LIVER DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE MARKER; DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; PREDICTION;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KI-67 ANTIGEN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTEIN PRECURSORS; PROTHROMBIN; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN;

EID: 0036809009     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2002.01541.x     Document Type: Article

References (28)

1. CIECHANOVER A, ELIAS S, HELLER H, FERBER S, HERSHKO A. Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes. J Biol Chem 1980; 255: 7525-8.
2. HERSHKO A, CIECHANOVER A, ROSE I A. Identification of the active amino acid residue of the polypeptide of ATP-dependent protein breakdown. J Biol Chem 1981; 256: 1525-8.
3. SCHLESINGER D H, GOLDSTEIN G, NIALL H D. The complete amino acid sequence of ubiquitin, an adenylate cyclase stimulating polypeptide probably universal in living cells. Biochemistry 1975; 14: 2214-8.
4. RECHSTEINER M. Ubiquitin-mediated pathways for intracellular proteolysis. Annu Rev Cell Biol 1987; 3: 1-30.
5. HERSHKO A. Ubiquitin-mediated protein degradation. J Biol Chem 1988; 263: 15237-40.
6. HERSHKO A, HELLER H, EYTAN E, REISS Y. The protein substrate-binding site of the ubiquitin-protein ligase system. J Biol Chem 1986; 261: 11992-9.
7. CIECHANOVER A, SCHWARTZ A L. How are substrates recognized by the ubiquitin-mediated proteolytic system? Trends Biochem Sci 1989; 14: 483-8.
8. JENTSCH S, SEUFERT W, SOMMER T, REINS H A. Ubiquitin-conjugating enzymes: novel regulators of eukaryotic cells. Trends Biochem Sci 1990; 15: 195-8.
9. HERSHKO A. The ubiquitin pathway for protein degradation. Trends Biochem Sci 1991; 16: 265-8.
10. RECHSTEINER M. Natural substrates of the ubiquitin proteolytic pathway. Cell 1991; 66: 615-8.
11. PICKART C M. Ubiquitin enters the new millennium. Mol Cell 2001; 8: 499-504.
12. SCHLESINGER M J, HERSHKO A, eds. The Ubiquitin System. Cold Spring Harbor, NY. Cold Spring Harbor Laboratory.
13. HAAS A L, WARMS J V, HERSHKO A, ROSE I A. Ubiquitin-activating enzyme. Mechanism and role in protein-ubiquitin conjugation. J Biol Chem 1982; 257: 2543-8.
14. GALLOWAY P G, LIKAVEC M J. Ubiquitin in normal, reactive and neoplastic human astrocytes. Brain Res 1989; 500: 343-51.
15. KANAYAMA H, TANAKA K, AKI M, et al. Changes in expressions of proteosome and ubiquitin genes in human renal cancer cells. Cancer Res 1991; 51: 6677-85.
16. ISHIBASHI Y, TAKADA K, JOH K, OKAWA K, AOKI T, MATSUDA M. Ubiquitin immunoreactivity in human malignant tumors. Br J Cancer 1991; 63: 320-2.
17. MARIN F, CHENG Z, KOVACS K. Ubiquitin immunoreactivity in corticotrophs following glucocorticoid treatment and in pituitary adenomas. Arch Pathol Laboratory Med 1993; 117: 254-8.
18. OSADA T, SAKAMOTO M, NISHIBORI H, et al. Increased ubiquitin immunoreactivity in hepatocellular carcinomas and pre-cancerous lesions of the liver. J Hepatol 1997; 26: 1266-73.
19. LIEBMAN H A, FURIE B C, TONG M J, et al. Des-r-carboxy prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 1427-31.
20. TAMANO M, SUGAYA H, OGUMA M, et al. Immunolocalisation of PIVKA-II in paraffin-embedded specimens of hepatocellular carcinoma. Liver 1999; 19: 406-10.
21. KAPLAN E L, MEIER P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
22. PAGANO M, TAM S W, THEODORAS A M, et al. Role of the ubiquitin-proteosome pathway in regulating abundance of the cyclin-dependent kinase inhibitor P27. Science 1995; 269: 682.
23. SHIRANE M, HARUMIYA Y, ISHIDA N, et al. Down-regulation of P27 Kip1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 1999; 274: 13886.
24. NAKAYAMA K, NAKAYAMA K. Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development. Biossays 1998; 20: 1020.
25. DEANNA M, KOEPP J, HARPER W, ELLEDGE S J. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999; 97: 431-4.
26. SALGHETTI S E, MURATANI M, WIJNEN H, FUTCHER B, TANSEY W P. Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc Nat Acad Sci USA 2000; 97: 3118-23.
27. GRIGIONI W F, D'ERRICO A, BACCI F, et al. Primary liver neoplasms: evaluation of proliferative index using Moab Ki67. J Pathol 1989; 158: 23-9.
28. KING K L, HWANG J J, CHAU G Y, et al. Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1998; 13: 273-9.